Ideaya to license ADC from Biocytogen

Ideaya Bioscience has secured an agreement with Beijing-based biotech company Biocytogen Pharmaceuticals to explore a potential first-in-class bispecific ADC program. This collaboration aims to develop an advanced treatment method targeting various solid tumor types.

Biocytogen's innovative B7H3/PTK7 topo-I-payload ADC program shows promise as a monotherapy for multiple solid tumors. Additionally, it may complement Ideaya's existing pipeline in focusing on DNA damage repair (DDR) therapies, such as the PARG inhibitor IDE161, which is a significant part of their research.

Regarding the financial aspects of the agreement, Biocytogen will receive an initial upfront fee. Should Ideaya decide to exercise its option, an additional fee will be paid, bringing the total to as much as $6.5 million. Furthermore, Biocytogen stands to gain up to $400 million through various milestone payments. These payments include up to $100 million in development and regulatory milestones, reflecting the potential value and impact of this collaboration.

Earlier in the same month, Biocytogen entered into another licensing agreement with Czech biotech company Sotio. This agreement involved multiple bispecific antibodies created using Biocytogen's proprietary RenLite platform. Sotio aims to expand its advanced ADC portfolio with these antibodies, highlighting the increasing interest and development in the bispecific ADC sector.

As the bispecific antibody and ADC fields evolve, bispecific ADCs are emerging as a next-generation approach in cancer treatment. This new modality promises to address some of the clinical challenges that ADCs face, such as off-target toxicity and drug resistance, thereby potentially offering more effective and safer treatment options.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!